PNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals

Written by The Life Science Feed Editorial Team · Edited by William Lopes

Paroxysmal nocturnal hemoglobinuria (PNH) presents a chronic, life-threatening challenge, driven by uncontrolled complement activation. For years, the focus remained on inhibiting the terminal complement pathway, specifically C5. But the clinical reality for many patients, even those on established therapies, revealed persistent disease activity and unmet needs.

This persistent disease activity pushed the field to reconsider its approach, shifting towards targeting the complement cascade at a more proximal level. The goal: achieve more comprehensive control over intravascular and extravascular hemolysis, and ultimately, improve patient outcomes beyond what C5 inhibition alone could offer.

KEY TAKEAWAYS

- The Pivot: Treatment goals for PNH have moved from solely preventing intravascular hemolysis to also addressing extravascular hemolysis and reducing transfusion dependence.
- The Data: Proximal complement inhibition has demonstrated the ability to achieve higher rates of transfusion independence and normalisation of hemoglobin levels compared to C5 inhibitors.
- The Action: Clinicians should consider the broader spectrum of complement inhibition when evaluating treatment options for PNH patients, particularly those with suboptimal responses to C5 inhibitors.

Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells, characterised by the absence of glycosylphosphatidylinositol (GPI)-anchored proteins, specifically CD55 and CD59, on the surface of red blood cells. These proteins normally protect red blood cells from complement-mediated destruction. Their absence renders PNH erythrocytes highly susceptible to lysis by the complement system, leading to chronic intravascular hemolysis, anemia, fatigue, thrombosis, and impaired quality of life. The disease is heterogeneous, with some patients experiencing severe, life-threatening complications, while others have a more indolent course. Diagnosis typically involves flow cytometry to detect GPI-deficient cells, a critical step for identifying eligible patients for targeted therapies. The chronic nature of the disease and its severe complications, particularly thrombotic events, underscore the need for effective and sustained complement inhibition.

Before the advent of targeted complement inhibitors, management of PNH was largely supportive, focusing on transfusions for anemia and anticoagulation for thrombosis prophylaxis. These measures, while necessary, did not address the underlying pathophysiology of uncontrolled complement activation. Patients faced a significantly reduced life expectancy, with a substantial proportion succumbing to thrombotic complications or infections. The unmet need

was profound, driving the search for therapies that could directly modulate the complement system and prevent red blood cell destruction. This historical context is vital for understanding the transformative impact of complement inhibition and the subsequent evolution of treatment paradigms.

The C5 Inhibition Era: A First Step

The introduction of eculizumab, a monoclonal antibody targeting the C5 component of the complement cascade, marked a significant milestone in PNH treatment. Eculizumab effectively blocks the formation of the membrane attack complex (MAC), preventing intravascular hemolysis. This led to dramatic improvements in transfusion requirements, reduction in thrombotic events, and enhanced survival for many patients. For the first time, clinicians had a therapy that directly addressed the core mechanism of PNH, moving beyond symptomatic management. The drug became the standard of care, fundamentally altering the prognosis for patients with severe PNH.

But C5 inhibition, while revolutionary, did not provide a complete solution for all patients. A significant proportion continued to experience persistent anemia and transfusion dependence, even with optimal C5 blockade. This phenomenon, often termed 'extravascular hemolysis,' occurs when C3b opsonisation of red blood cells leads to their removal by macrophages in the reticuloendothelial system, primarily the spleen and liver. C5 inhibitors do not prevent C3 activation, meaning C3b deposition on PNH red cells can still occur. This persistent extravascular hemolysis became a major clinical challenge, highlighting the limitations of targeting only the terminal pathway.

The patient population experiencing suboptimal response to C5 inhibitors was diverse. It included those with persistent anemia requiring ongoing transfusions, those with chronic fatigue despite reduced hemolysis, and some who developed resistance or intolerance to C5 blockade. These patients represented a clear unmet need, prompting further research into alternative strategies for complement inhibition. The goal was no longer just to prevent intravascular hemolysis, but to achieve complete complement control, encompassing both intravascular and extravascular components of red blood cell destruction. This broader therapeutic ambition necessitated a deeper understanding of the complement cascade and its points of intervention.

Moving Upstream: Proximal Complement Inhibition

The recognition of persistent extravascular hemolysis spurred interest in targeting earlier, or 'proximal,' components of the complement cascade. Inhibiting C3, for instance, prevents the formation of both C3b and the subsequent C5 activation, thereby addressing both intravascular and extravascular hemolysis. This upstream approach promised a more comprehensive blockade of complement-mediated red blood cell destruction. The theoretical advantage was clear: by stopping the cascade earlier, one could prevent the opsonisation that drives extravascular hemolysis, in addition to blocking MAC formation.

Several investigational therapies emerged, focusing on different proximal targets within the complement system. These included C3 inhibitors, factor B inhibitors, and factor D inhibitors. Each of these targets plays a critical role in the alternative pathway, which is particularly active in PNH due to the lack of regulatory proteins. By inhibiting these upstream components, the aim was to achieve a more profound and sustained suppression of complement activity, leading to better hematological responses and reduced transfusion burden. The development of these agents represented a deliberate shift in therapeutic strategy, moving from a reactive approach to a more proactive and comprehensive one.

The patient populations studied for these proximal inhibitors often included those who had previously responded

inadequately to C5 inhibitors, or those who were treatment-naïve but presented with severe disease. The primary endpoints in these studies typically focused on transfusion independence and normalisation of hemoglobin levels, reflecting the desire to overcome the limitations of C5 blockade. Secondary endpoints often included improvements in fatigue scores, quality of life, and reduction in lactate dehydrogenase (LDH) levels, a biomarker for intravascular hemolysis. The comprehensive nature of these endpoints underscored the ambition to achieve not just survival, but a return to a near-normal quality of life for PNH patients. For a deeper dive into how real-world data supports this shift, consider our previous coverage on proximal complement inhibition in PNH.

The Numbers: A New Standard for Response

Clinical trials evaluating proximal complement inhibitors have demonstrated compelling results, particularly in patients who remained anemic or transfusion-dependent on C5 inhibitors. These newer agents have shown the ability to achieve higher rates of transfusion independence, with some studies reporting rates exceeding 80% in previously C5-inhibitor-treated patients. This is a significant improvement over the rates observed with C5 inhibitors alone, where persistent transfusion dependence remained a common issue. Normalisation of hemoglobin levels, defined as achieving a hemoglobin concentration above 12 g/dL without transfusions, has also been a key outcome, with proximal inhibitors showing superior performance in this regard.

The reduction in LDH levels, a marker of intravascular hemolysis, has been consistently observed with proximal inhibitors, often to levels comparable to or even lower than those achieved with C5 inhibitors. But the true differentiator has been the impact on extravascular hemolysis, as evidenced by the substantial reduction in transfusion requirements. Patients who previously needed regular blood transfusions to maintain adequate hemoglobin levels have been able to achieve transfusion independence for extended periods. This has a profound impact on patient quality of life, reducing hospital visits and the associated risks of transfusion reactions and iron overload. For clinicians seeking a comprehensive reference on haematological conditions, the Oxford Handbook of Clinical Haematology (4th ed) offers valuable insights into managing complex cases like PNH.

Safety profiles for these proximal inhibitors have generally been manageable, though specific considerations exist for each agent. Complement inhibition, by its nature, increases the risk of infection, particularly encapsulated bacterial infections. Patients receiving these therapies require appropriate vaccinations and prophylactic antibiotics, similar to those on C5 inhibitors. The long-term safety data are still accumulating, but the benefits in terms of hematological response and quality of life appear to outweigh the risks for many patients with severe or refractory PNH. The shift in treatment goals is not just about survival, but about achieving a higher standard of disease control and patient well-being.

Where the Field Still Falls Short

Despite the advancements, challenges remain. The high cost of complement inhibitors, both C5 and proximal, presents a significant barrier to access in many healthcare systems. This economic burden can limit the widespread adoption of these therapies, even for patients who would benefit most. The need for lifelong treatment means these costs accumulate over time, posing long-term sustainability questions for healthcare budgets. The development of biosimilars or more cost-effective alternatives is an ongoing area of interest, but progress has been slow.

Another limitation is the potential for breakthrough hemolysis, even with proximal inhibitors. While less common than with C5 inhibitors, some patients may still experience episodes of hemolysis due to various factors, including intercurrent

infections, stress, or inadequate dosing. Managing these breakthrough events requires careful clinical monitoring and prompt intervention. The optimal dosing and monitoring strategies for these newer agents are still being refined, and individual patient responses can vary significantly. The heterogeneity of PNH itself means that a one-size-fits-all approach is rarely sufficient.

The long-term impact of sustained proximal complement inhibition on immune function and infection risk also warrants continued surveillance. While current data suggest a manageable safety profile, the implications of prolonged, broad complement blockade need to be thoroughly understood over decades. This is particularly relevant for younger patients who will be on these therapies for the majority of their lives. The field continues to explore strategies to mitigate infection risk, including novel vaccine approaches and more targeted prophylactic regimens. The goal is to balance effective disease control with minimal adverse effects, ensuring both efficacy and safety for patients with PNH.

CLINICAL IMPLICATIONS

The evolution of PNH treatment from C5 inhibition to proximal complement blockade represents a clear step forward for patients. For too long, clinicians accepted persistent anemia and transfusion dependence as an unavoidable consequence of C5 inhibitor therapy. The data now compel us to aim higher, particularly for those patients who remain symptomatic despite adequate C5 blockade.

The availability of proximal inhibitors means that persistent extravascular hemolysis is no longer an acceptable endpoint. Clinicians should proactively assess patients on C5 inhibitors for suboptimal responses, considering a switch to a more comprehensive complement inhibitor if transfusion dependence or significant anemia persists. This requires a shift in mindset, moving beyond mere survival to achieving a truly normal hematological status.

But the cost implications are substantial. Healthcare systems must grapple with the economic burden of these highly effective, but expensive, therapies. Balancing patient access with fiscal responsibility will be a continuous challenge, potentially driving innovation in drug delivery or the development of more affordable alternatives. The conversation around value-based care in rare diseases will only intensify.

The goal is to normalise the lives of PNH patients as much as possible. This means not just preventing life-threatening complications, but also eliminating the chronic fatigue and transfusion burden that significantly impair quality of life. Proximal inhibition offers a pathway to this more ambitious goal, setting a new standard for what constitutes effective PNH management.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Waheed A, Shammo J, Dingli D. Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape. Blood Rev. 2024;64:101158. doi:10.1016/j.blre.2023.101158

2.

2. Godby RC, Shah S. Paroxysmal Nocturnal Hemoglobinuria. Mayo Clin Proc. 2025;100(12):2206-2227. doi:10.1016/j.mayocp.2025.07.029

3. 3. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-11. doi:10.1182/blood-2014-02-522128

4. 4. Kokoris S, Polyviou A, Evangelidis P, et al. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment. Int J Mol Sci. 2024;25(22). doi:10.3390/ijms252212104

5. 5. Bravo-Perez C, Guarnera L, Williams ND, Visconte V. Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment. Medicina (Kaunas). 2023;59(9). doi:10.3390/medicina59091612

6. 6. Versino F, Fattizzo B. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. Int J Lab Hematol. 2024;46 Suppl 1:43-54. doi:10.1111/ijlh.14281

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.